|
|
 |
|
|
|
|
Regulatory process in Japan, 354-361 |
|
|
|
|
|
|
|
|
Remifentanil, 302-304 |
|
|
|
|
|
|
|
|
Remote data entry (RDE), 347 |
|
|
|
|
|
|
|
|
Research, 14 |
|
|
|
|
|
|
|
|
government, 15 |
|
|
|
|
|
|
|
|
Research and development |
|
|
|
|
|
|
|
|
balance between, 85-86 |
|
|
|
|
|
|
|
|
budget, 83-85 |
|
|
|
|
|
|
|
|
costs, 69-71, 80-81, 83-85 |
|
|
|
|
|
|
|
|
factors affecting, 86-101 |
|
|
|
|
|
|
|
|
differences between, 81-83 |
|
|
|
|
|
|
|
|
portfolio, 101-114 |
|
|
|
|
|
|
|
|
Resperine, 4 |
|
|
|
|
|
|
|
|
Scaling, 229-235 |
|
|
|
|
|
|
|
|
in vitro, 230-232 |
|
|
|
|
|
|
|
|
in vivo, 232-235 |
|
|
|
|
|
|
|
|
Single European Act, 422 |
|
|
|
|
|
|
|
|
Single photon emission tomography (SPECT), 248 |
|
|
|
|
|
|
|
|
Sorbitol, 123 |
|
|
|
|
|
|
|
|
Starch, 123 |
|
|
|
|
|
|
|
|
pregelatinized, 123 |
|
|
|
|
|
|
|
|
Structure-based drug design (SBDD), 207 |
|
|
|
|
|
|
|
|
Sucrose, 122 |
|
|
|
|
|
|
|
|
SVT, 12 |
|
|
|
|
|
|
|
|
Synthetic discovery, 6 |
|
|
|
|
|
|
|
|
System Response Correlation Concept, 118, 161-167 |
|
|
|
|
|
|
|
|
T peak, 145 |
|
|
|
|
|
|
|
|
Targeted therapy, 187-190 |
|
|
|
|
|
|
|
|
Technology (ies), 27 |
|
|
|
|
|
|
|
|
Tools for Structure Activity Relationships (TSAR), 223 |
|
|
|
|
|
|
|
|
Total Quality Management (TQM) techniques, 96 |
|
|
|
|
|
|
|
|
Toxicokinetics, 251, 266 |
|
|
|
|
|
|
|
|
Transdermal drug delivery, 176-179 |
|
|
|
|
|
|
|
|
Wickline liability, 64 |
|
|
|
|
|